Download PDF
Senologie - Zeitschrift für Mammadiagnostik und -therapie 2024; 21(03): 208-218
DOI: 10.1055/a-2256-4201
Übersicht

Die Sentinel-Lymphknoten-Biopsie beim Mammakarzinom – was haben wir in den letzten 20 Jahren gelernt?

Sentinel lymph node biopsy in breast cancer – what have we learned in the last 20 years?
Thorsten Kühn
1   Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Deutschland (Ringgold ID: RIN27197)
2   Gynäkologische Onkologie, Die Filderklinik, Filderstadt-Bonlanden, Deutschland
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Vor gut 20 Jahren wurde die Sentinel-Lymphknoten-Biopsie (SLNB) als Standardverfahren für das axilläre Staging beim invasiven Mammakarzinom eingeführt und ersetzte die über Jahrzehnte etablierte Axilladissektion (ALND), bei der alle Lymphknoten aus den Leveln 1 und 2 aus diagnostischer und/oder therapeutischer Indikation entfernt wurden. Dabei stellte die Implementierung der SLNB lediglich den ersten Schritt zu einer kontinuierlichen Deeskalation der Lymphknoten-Chirurgie dar. Diese Entwicklung begründete sich mit dem zunehmenden Ersatz prognostischer Faktoren durch prädiktive Marker für adjuvante Therapieentscheidungen, die Möglichkeit, das Tumorstadium durch eine vorgeschaltete Chemotherapie (NACT) herabzustufen sowie die Bestätigung älterer Studien, die bereits sehr frühzeitig den therapeutischen Benefit einer ALND in Zweifel gezogen haben. Bei Patientinnen, die eine primäre Operation erhalten, werden zunehmend Kollektive identifiziert, bei denen gar keine SLNB mehr durchgeführt werden muss. Auch die therapeutische ALND ist bei Frauen mit einem positiven SLN nur noch in Ausnahmefällen erforderlich. Die Einführung der SLNB nach einer NACT bei Patientinnen mit primär unauffälligen Lymphknoten erlaubte nicht nur die verlässliche Beurteilung der Tumorresponse, sondern auch eine Reduktion der ALND-Rate durch die Konversion des Nodalstatus bei vielen Patientinnen. Bei nodalpositiven Frauen, die unter Chemotherapie zu einem klinisch unauffälligen Lymphknotenstatus konvertieren, setzt sich zunehmend die Targeted Axillary Dissection als neuer operativer Standard durch.

Abstract

Twenty years ago, Sentinel Node Biopsy (SLNB) was introduced as a standard procedure for surgical staging of the axilla in invasive breast cancer and replaced full axilla lymph node dissection (ALND) with complete removal of all lymph nodes from level 1 and 2 which was performed over decades as surgical standard for diagnostic and/or therapeutic purposes. The implementation of SLNB was a first step in a continuous process to deescalate axillary surgery in recent years. This evolution was based on the replacement of prognostic factors by predictive markers for the decision making of adjuvant treatment, the option to downgrade the tumor stage by neoadjuvant chemotherapy (NACT) and the confirmation of early trials that doubted the therapeutic effect of ALND. In patients who undergo primary surgery increasing cohorts are identified in whom SLNB can be omitted at all. In addition, therapeutic ALND in SLN positive patients is only required in few patients. The introduction of SLNB after NACT in primarily unsuspicious nodes not only allowed the assessment of tumor response but also a reduction of the ALND rate for many patients – due to the conversion of the lymph node status. For node-positive patients, who convert under NACT from node-positive to node-negative, targeted axillary dissection is increasingly established as a surgical standard.

Schlüsselwörter

Brustkrebs - Operation - Lymphknoten - Lymph Nodes

Keywords

Breast Cancer - Surgery


Publication History

Article published online:
13 September 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Fisher B, Redmond C. et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with and without radiation N Engl. J Med 1985; 312: 674-681
    PubMedGoogle Scholar
  • 2 Kühn T, Klauss W, Darsow M. et al. Long-term morbidity following axillary dissection in breast cancer patients – clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat 2000; 64: 275-286
    CrossrefPubMedGoogle Scholar
  • 3 Kühn T, Santjohanser C, Grab D. et al. Endoscopic axillary surgery in breast cancer. Brit J Surg 2001; 88: 698-703
    CrossrefPubMedGoogle Scholar
  • 4 Krag DN, Weaver DJ. et al. Surgical Resection and radiolocalisation of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2: 335-339
    CrossrefPubMedGoogle Scholar
  • 5 Krag D, Weaver D. et al. The sentinel node in breast cancer – a multicenter validation study. N Engl J Med 1998; 339: 941-946 DOI: 10.1056/NEJM199810013391401. (PMID: 9753708)
    CrossrefPubMedGoogle Scholar
  • 6 Kuehn T, Vogl FD, Helms G. et al. Sentinel-Node-Biopsy is a reliable method for axillary staging in Breast Cancer: Results from a large Prospective German Multi-Institutional Trial. Eur J Surg Oncol 2004; 30: 252-259
    CrossrefPubMedGoogle Scholar
  • 7 Veronesi U, Paganelli C. et al. A randomized comparison of sentinel node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003; 349: 546-553
    CrossrefPubMedGoogle Scholar
  • 8 Krag DN, Anderson SJ. et al. Sentinel-Lymph-Node Resection compared with conventional axillary lymph node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomized phase 3 trial. Lancet Oncol 2010; 11: 927-933
    CrossrefPubMedGoogle Scholar
  • 9 Kuehn T, Bembenek A, Decker T. Consensus Committee of the German Society of Senology. et al. A concept for the clinical implementation of sentinel lymph node biopsy (SLNB) in breast cancer patients with special regard to quality assurance. Cancer 2005; 103: 451-461
    CrossrefPubMedGoogle Scholar
  • 10 Klimberg VS, Rubio IT. et al. Subareolar versus peritumoral injection for localization of the sentinel node. Ann Surg 1999; 229: 860-864
    CrossrefPubMedGoogle Scholar
  • 11 Rocco N, Velotti N. New techniques versus standard mapping for sentinel lymph node biopsy in breast cancer: a systematic review and metaanalysis. Updates in Surgery 2023; 75: 1699-1710 DOI: 10.1007/s13304-023-01560-1. (PMID: 37326934)
    CrossrefPubMedGoogle Scholar
  • 12 Rudenstam CM. et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group trial 10–93. J Clin Oncol 2006; 24: 337-344
    CrossrefPubMedGoogle Scholar
  • 13 Giuliano AE. et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. A randomized trial. JAMA 2011; 305: 569-575
    CrossrefPubMedGoogle Scholar
  • 14 Galimberti V. et al. Axillary dissection versus no axillary dissection in patients with micrometastases (IBCSG 1–23) a phase 3 randomized trial. Lancet Oncol 2013; 14: 297-305
    CrossrefPubMedGoogle Scholar
  • 15 Tinterri C. et al. Preservation of axillary lymph nodes compared with complete dissection in T1/T2 breast cancer patients presenting 1 or 2 metastatic sentinel lymph nodes: The SINODAR-ONE multicenter randomized trial. Ann Surg Oncol 2022; 29: 5732-5744 DOI: 10.1245/s10434-022-11866-w. (PMID: 35552930)
    CrossrefPubMedGoogle Scholar
  • 16 De Boniface J. et al. Omitting axillary dissection in breast cancer with sentinel-node metastases N Engl. J Med 2024; 390: 1163-1175
    PubMedGoogle Scholar
  • 17 Park-Simon TW. et al. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the diagnosis and treatment of patients with early breast cancer: Update 2023. Breast Care 2023; 18: 289-305
    CrossrefPubMedGoogle Scholar
  • 18 Harbeck N, Rastogi P, Martin M. et al. MonarchE Committee Members. Adjuvant Abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021; 32: 1571-1581
    CrossrefPubMedGoogle Scholar
  • 19 Slamon D, Lipatov O, Nowecki Z. et al. Ribociclib plus endocrine therapy in early breast cancer. New Engl J Med 2024; 390: 1080-1091 DOI: 10.1056/NEJMoa2305488. (PMID: 38507751)
    CrossrefPubMedGoogle Scholar
  • 20 Gentilini OD. et al. Sentinel Lymph Node Biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes – The SOUND randomized clinical trial. JAMA Oncol 2023; DOI: 10.1001/jamaoncol.2023.3759.
    CrossrefPubMedGoogle Scholar
  • 21 Reimer T. et al. Patient-reported outcomes for the intergroup Sentinel Mamma study (INSEMA): A randomized trial with persistent impact on axillary surgery on arm and breast symptoms in patients with early breast cancer. eClinicalMedicine 2022; 55: 101756
    CrossrefPubMedGoogle Scholar
  • 22 Kuehn T, Bauerfeind I, Fehm T. et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013; 14: 609-618
    CrossrefPubMedGoogle Scholar
  • 23 Classe JM. et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat2019; Breast Cancer Res Treat 2019; 173: 343-352 DOI: 10.1007/s10549-018-4944-2. (PMID: 30238274)
    CrossrefPubMedGoogle Scholar
  • 24 Boughey JC. et al. Sentinel Lymph Node Biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310: 1455-1461
    CrossrefPubMedGoogle Scholar
  • 25 Donker M. et al. Marking axillary lymph nodes with radioactive Iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg 2015; 261: 378-382
    CrossrefPubMedGoogle Scholar
  • 26 Caudle AS, Yang WT, Krishnamurthy S. et al. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol 2016; 34: 1072-1078
    CrossrefPubMedGoogle Scholar
  • 27 Kümmel S. et al. A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-positive breast cancer patients. Ann Surg 2022; 276: e553-e562
    CrossrefPubMedGoogle Scholar
  • 28 Montagna G. et al. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy. JAMA Oncol 2024; DOI: 10.1001/jamaoncol.2024.0578.
    CrossrefPubMedGoogle Scholar
  • 29 Banys-Paluchowski M. et al. Surgical Management of the Axilla in Clinically Node-Positive Breast Cancer Patients Converting to Clinical Node Negativity through Neoadjuvant Chemotherapy: Current Status, Knowledge Gaps and Rationale for the EUBREAST-03 AXSANA Study. Cancers 2021; 13: 1565
    CrossrefPubMedGoogle Scholar
  • 30 Simons J. et al. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla with Sentinel Lymph Node Biopsy After neoadjuvant Chemotherapy in Node-Positive Breast Cancer. JAMA Surg 2022; 57: 991-999
    CrossrefPubMedGoogle Scholar
  • 31 Hartmann S. Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study. Breast Cancer Res Treat 2023; DOI: 10.1007/s10549-023-07100-0. (PMID: 37684426)
    CrossrefPubMedGoogle Scholar
  • 32 Kantor O, Sipsy LM, Yao K. et al. A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer. Annals of surgical oncology 2018; 25: 1304-1311 DOI: 10.1245/s10434-018-6345-5. (PMID: 29368152)
    CrossrefPubMedGoogle Scholar
  • 33 Sanne AL. et al. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981–22023 AMAROS Tria. J Cin Oncol 2022; 41: 2159-2165
    PubMedGoogle Scholar
  • 34 De Boer M. et al. Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer. New Engl J Med 2009; 361: 653-63 DOI: 10.1056/NEJMoa0904832. (PMID: 19675329)
    CrossrefPubMedGoogle Scholar
  • 35 Classe JM. et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiothérapie Néoadjuvante, a French prospective multicentric study. J Clin Oncol 2009; 27: 726-732 DOI: 10.1200/JCO.2008.18.3228. (PMID: 19114697)
    CrossrefPubMedGoogle Scholar
  • 36 Moo TA. et al. Is Low-Volume Disease in the Sentinel Node After neoadjuvant Chemotherapy an Indication for Axillary Dissection. Ann Surg Oncol 2018; 25: 1488-1494 DOI: 10.1245/s10434-018-6429-2. (PMID: 29572705)
    CrossrefPubMedGoogle Scholar
  • 37 Wong S. et al. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol 2019; 26: 3502-3509 DOI: 10.1245/s10434-019-07517-2. (PMID: 31228134)
    CrossrefPubMedGoogle Scholar
  • 38 Bartels SAL, Donker M, Poncet C. et al. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. J Clin Oncol 2023; 41: 2159-2165 DOI: 10.1200/JCO.22.01565.
    CrossrefPubMedGoogle Scholar